Abstract CT093: Axitinib in combination with pembrolizumab (AXI+PEMBRO) in patients (pts) with advanced renal cell carcinoma (aRCC): Analysis of immune-related biomarkers

Authors: Michael Atkins, Jean-Francois Martini, Elizabeth Plimack, David McDermott, Igor Puzanov, Mayer Fishman, Daniel Cho, Ulka Vaishampayan, Brad Rosbrook, Kathrine Fernandez, Jamal Tarazi, Saby George, Toni Choueiri

Published: 2019-08-07

DOI: 10.1158/1538-7445.am2019-ct093

Source: Full article